We can’t show the full text here under this license.
Temozolomide chemotherapy for new glioblastoma patients: Does the timing of treatment affect outcomes?
Updated
Abstract
In a cohort of 810 glioblastoma patients, 39% received temozolomide in the morning.
- No significant difference in was observed between patients taking temozolomide in the morning and those taking it in the evening.
- In the CENTRIC trial, the median overall survival was 20.6 months for morning administration and 21.1 months for evening administration.
- In the CORE trial, the median overall survival was 10.9 months for morning administration and 11.4 months for evening administration.
- Morning administration of temozolomide was associated with a higher incidence of compared to evening administration.
- Bone marrow toxicity rates were 33% for morning versus 11% for evening in CENTRIC, and 24% for morning versus 3% for evening in CORE.
Simplified
Key numbers
20.6 months
Median in CENTRIC
Adjusted median for morning vs. evening administration.
33%
Higher Rate
Proportion of patients with in CENTRIC.
5.3 months
Longer in CORE
Adjusted median for morning vs. evening administration in CORE.